Opus Genetics (IRD) Enterprise Value (2010 - 2026)

Opus Genetics (IRD) has reported Enterprise Value for 17 consecutive years, with -$60.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 43.56% year-over-year to -$60.0 million; the TTM figure through Mar 2026 stood at -$60.0 million (down 43.56% YoY), while the FY2025 annual figure was -$45.1 million, down 48.7% from the prior year.
• Enterprise Value fell to -$60.0 million in Q1 2026 per IRD's latest filing, from -$45.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$14.0 million in Q3 2022 and bottomed at -$60.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$37.1 million across 5 years, with a median of -$40.0 million in 2023.
• Annual changes were most pronounced in 2023 — Enterprise Value tumbled 203.53% — and 2024, when it surged 39.97%.
• Opus Genetics' Enterprise Value stood at -$42.7 million in 2022, then declined by 18.35% to -$50.5 million in 2023, then soared by 39.97% to -$30.3 million in 2024, then sank by 48.7% to -$45.1 million in 2025, then slumped by 33.06% to -$60.0 million in 2026.
• Business Quant data shows IRD's Enterprise Value at -$60.0 million in Q1 2026, -$45.1 million in Q4 2025, and -$30.8 million in Q3 2025.